Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott's Future Dual Glucose-Ketone Sensor

Core Insights - Beta Bionics, Inc. plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott's upcoming dual glucose-ketone sensor in the U.S. market [1][2][3] Company Overview - Beta Bionics is a commercial-stage medical technology company focused on simplifying diabetes management and improving outcomes for individuals requiring insulin therapy [3] - The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device featuring a fully autonomous insulin dosing algorithm, setting a new standard in diabetes care [3] Product Features - The iLet system is the first and only automated insulin delivery system that makes 100% of insulin dosing decisions automatically, allowing users to achieve excellent clinical outcomes without the need for carb counting or manual insulin correction calculations [2] - Currently, the iLet supports Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor, and the future integration with Abbott's dual glucose-ketone sensor is expected to enhance real-time decision-making support for diabetes management [2][3]